Status:
COMPLETED
The Value of MultiSpectral 3 Tesla MRI in Active Surveillance of Prostate Cancer
Lead Sponsor:
Sunnybrook Health Sciences Centre
Collaborating Sponsors:
Philips Healthcare
Conditions:
Prostate Cancer
Eligibility:
MALE
18+ years
Phase:
NA
Brief Summary
MultiSpectral 3 Tesla MRI (MS3TMRI) can increase the yield of Trans Rectal Ultrasound Biopsy (TRUSBx) to improve identification of patients on active surveillance requiring treatment.
Detailed Description
This is a prospective single arm study. 120 patients at risk for significant occult prostate cancer on an active surveillance program will undergo MS3TMRI followed by a standard TRUSBx and additional ...
Eligibility Criteria
Inclusion
- Enrolled in active surveillance at Sunnybrook Health Sciences Centre, requiring biopsy as part of surveillance protocol.
- Clinically eligible for radical prostatectomy and willing to undergo surgery
- Clinically eligible for and willing to undergo ultrasound biopsy within 8 weeks of MRI
Exclusion
- Claustrophobia
- Contraindication to MRI
- Contraindication to receiving low molecular weight MRI contrast agent
- Prior hormone therapy except 5-alpha reductase inhibitors such as Avodart. FloMax etc
- Clinically suspected or known compromised renal function or calculated estimated Glomerular Filtration Rate (eGFR) \<30ml/min
Key Trial Info
Start Date :
April 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2012
Estimated Enrollment :
81 Patients enrolled
Trial Details
Trial ID
NCT01896713
Start Date
April 1 2010
End Date
December 1 2012
Last Update
July 11 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Sunnybrook Health Sciences Centre
Toronto, Ontario, Canada, M4N 3M5